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In the past few decades, the use of cardiac rhythm man-
agement (CRM) devices has increased worldwide due to the
increase in life expectancy and technological developments
(e.g., cardiac resynchronization therapy) that have extended
their indications (1–4). When imaging is required in pa-
tients with CRM devices, computed tomography (CT) is
the preferred modality because magnetic resonance imaging
has been generally contraindicated (5–7).
CT scanning technology is ubiquitous and over the past
15 years has become routine in the evaluation of neurologic,
respiratory, cardiovascular, gastrointestinal, and other dis-
eases. Therefore, an increase in the number of patients with
CRM devices undergoing CT scanning at least once in their
lifetime is also expected.
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As the use of CT scans has skyrocketed, some experts
have raised concerns over the potential risk of patients’
increased exposure to radiation. Between 2006 and 2007,
several reports of CT interference with CRM device func-
tioning were published (8–10).
This led the U.S. Food and Drug Administration (FDA)
to issue in 2008 an advisory informing of possible mal-
function of CRM devices, such as inappropriate shocks from
implanted cardioverter-deﬁbrillators (ICDs) and transient
changes in permanent pacemaker (PPM) output pulse rate
that could result in failure to pace.
Was the FDA overreacting, or was this public health
notiﬁcation justiﬁed?
The FDA is responsible for overseeing the research,
development, and marketing of various foods, drugs, and
medical devices. However, some concern has been raised*Editorials published in the Journal of the American College of Cardiology reﬂect the
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this institution, and the use of CT scans in patients with
CRM devices might very well be a good example.
To answer this question, we have reviewed the scientiﬁc
data on which the FDA 2008 recommendations were based,
ﬁnding that there are scarce data about potential interference
on CRM device functioning from CT imaging. In fact, there
are only two peer-reviewed publications with limited evidence
of direct causality (8,9). In the study by Yamaji et al. (8), 6
of 11 patients with an implanted PPM showed transient
lead oversensing during chest CT scanning. Of note, none
of these were associated with any clinically signiﬁcant
event. Both that report (8) and one by McCollough et al. (9)
used in vitro phantom models to demonstrate the interaction
of ionized radiation with CRM devices, but studies of
conﬁrmed events in humans were lacking. Notably, as shown
by McCollough et al. (9), only some CRM devices were
sensitive to radiation exceeding certain dose rates, and these
interactions terminated immediately after the radiation beam
wasmoved out of the region of the device. Those investigators
could not provoke any permanent changes in the device
programming (9). We therefore believe that the FDA may
have been overzealous when issuing the 2008 advisory, on the
basis of the limited scientiﬁc information available at the
time. The main problem is that the results of these studies
may not be generalizable to the everyday clinical setting.
Since 2008, two additional reports have evaluated the
interaction of CT imaging with CRM functioning in vitro
(11,12). As in the previous studies, these experimental
studies suggested that the interference is dependent on the
radiation dose and the duration of the exposure and rec-
ommended lower x-ray doses and short periods of radiation.
In this issue of the Journal, Hussein et al. (13) assess the
effect on CRM devices of direct exposure to radiation beams
from CT imaging to further address these concerns in a
clinical setting. Data were drawn from the medical records
of 386 patients who underwent a total of 516 CT scans. The
primary outcome was a composite endpoint of death, un-
planned hospitalization, bradycardia or tachycardia requiring
termination of the CT scan or an immediate intervention,
inappropriate ICD shock, resetting or reprogramming of
the device, or device replacement/revision attributable to
radiation exposure. As a secondary endpoint, the authors
analyzed the occurrence of signiﬁcant changes in device pa-
rameters. Their main ﬁnding was that direct exposure to
radiation from CT imaging was not associated with any
clinically relevant adverse event, nor did it induce signiﬁcant
variations in battery voltage or electrode parameters.
The study by Hussein et al. (13) is of particular relevance for
several reasons: ﬁrst, it addresses a speciﬁc public health prob-
lem; second, it was designed and performed in a timely manner;
and third, it is of major importance not only in the clinical
community but also in the regulated industry and the FDA.
The few limitations of the reported analysis, acknowl-
edged by the authors, mainly derive from the retrospective
nature of the study. First, relevant variables such as radiation
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1777exposure (dose and duration, particularly over the device) were
not recorded. With regard to the evaluation of adverse events,
recording in the medical record could likely overlook “milder”
events (e.g., transient dizziness). However, “stronger” out-
comes (e.g., syncope or an inappropriate shock) would
doubtfully be left out. Also, device parameters were not ass-
essed immediately before and/or after CT scanning; therefore,
some transient changes may have been overlooked. Finally,
some clinically relevant events may have been overlooked due
to the small sample size (in relation to the hundreds of thou-
sands of patients with CRM devices undergoing CT scan-
ning). The authors are aware of this limitation, but as they
rightly stress, these would likely occur at a very low rate (0.2%).
From a practical perspective, the observational design of
the study by Hussein et al. (13) may actually make the study
results more, rather than less, important. The authors have
validated in an everyday setting that PPM and ICD responses
to radiation are transient and benign and that routine CT
scanning in patients with CRMdevices should not be restricted.
The authors are to be commended for having undertaken
such a study to clarify a clinical situation of major importance.
To date, hundreds of thousands of patients with some
type of CRM device have undergone CT scanning,
considering the widespread use of both, particularly in older
patients. The risks associated with imaging procedures are
small compared with other risks. For instance, of patients
with a PPM or ICD, some may require CT imaging for
the evaluation of lung tumor or for possible internal bleed-
ing after motor vehicle accidents. The relative risk from the
natural course of any disease requiring CT evaluation
compared to the risks of the imaging itself is remarkable.
Government institutions like the FDA are necessary to
ensure that effective therapies are made available to patients as
quickly as possible whereas ensuring that those therapies are
safe over the life cycle of a product. However, it is necessary to
be rigorous in order to avoid misleading and confounding. In
medicine, we continuously live with risk/beneﬁt ratios, and
we make reasoned judgments accordingly. We understand
that, in alleviating one problem, we may increase the risk for
another (e.g., anticoagulation for stroke prevention).
Unfortunately, these agencies, when trying to guarantee the
safety of a product, often neglect the potential of beneﬁt.
Furthermore, it is our belief that in this particular case, the
FDA may have been somehow reckless. Since the ﬁrst CT
scan on a patient in practice in 1971 (14), several hundred
thousand (probably millions) have undergone this test while
having an implanted PPM or ICD. Very few CT examination
types would have the radiation constant over the device beyond
2 s. Thus, common sense tells us that device interactions may,
in fact, be quite frequent but benign because the effect is
transient, lasting at most a few seconds. Indeed, 3 decades after
that ﬁrst CT scan, no cases of clinically major adverse events in
patients in practice have been described to the authorities or
published in the data. To answer our question, we believe that
the FDA was overreacting when issuing the 2008 advisory.We count on these regulatory agencies to provide us with a
well-deﬁned proﬁle of both potential toxicity and efﬁcacy, on
the basis of solid evidence. For that purpose, it is of major
importance that the FDA and other similar institutions work
hand in hand with clinicians to develop a post-marketing
structure that addresses new and ongoing concerns and iden-
tiﬁes early signals of potential problems in a sensible fashion,
always weighing the risk/beneﬁt to patients and taking into
account the accumulated experience of professionals.
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